Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)

Launched by UNIVERSITY OF ALBERTA · Sep 16, 2021

Keywords

ClinConnect Summary

The LIBERATE trial is studying a medication called midodrine, which is used to help raise blood pressure in patients who are critically ill in the intensive care unit (ICU). Typically, doctors give patients IV vasopressors to manage low blood pressure, but this study is exploring whether midodrine, an oral medication, can help reduce the need for these IV treatments as patients' blood pressure improves. This research aims to find out if midodrine can be an effective option for patients who are currently receiving support from vasopressors.

To participate in this trial, individuals must be over 18 years old and currently receiving vasopressor support with decreasing doses. However, those who are expected to pass away soon or who have certain medical conditions may not be eligible. If someone joins the trial, they can expect to receive midodrine while their doctors carefully monitor their blood pressure and overall health. This study is important as it could help improve treatment options for patients with low blood pressure in critical care settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • Ongoing vasopressor support
• • Decreasing vasopressor dose(s)
• Exclusion Criteria:
• • Greater than 24 hours from peak vasopressor dose
• • Contraindication to enteral medications
• • Previously received midodrine in last 7 days
• • Expected death or anticipated withdrawal of life-sustaining therapies in next 24 hours
• • Pregnancy
• • Known allergy to midodrine